[The Clinical Efficacy of Small Dose CAG Program in Comparison with MA Program in Senile Patients with Acute Myeloid Leukemia].
To compare the clinical efficacy of small dose CAG regimen and MA regimen in the senile patients with acute myeloid leukemia(AML). The clinical data of 83 senile patients with AML from Sep. 2012 to Sep. 2016 in our Hospital were analyzed retrospectively. According to the chemotherapy regimens, the patients were divided into CAG group and MA group; 36 patients in CAG group were treated with small dose CAG, while 47 patients in MA group were treated with MA. The curative efficiency(CR rate, PR rate,NR rate and OR rate), side effect (myelosuppression,infection,intestinal discomfort and hemorrage), serum cytokines(IL-6，IL-17，TGFβ）, and prognosis(survival rate in 2 years, MST and SST) were observed, compared and studied in these 2 group. The curative efficiency, CR rate and PR rate of the CAG group were not significantly different from that of the MA group (P>0.05）. The side effect in CAG group was significantly lower than that in the MA group (P<0.05）. The levels of serum cytokines of the MA group were lower than those of the CAG group. Additionally, the prognosis was not significantly different between 2 groups(P>0.05）. For senile patients with acute myeloid leukemia, compared with traditional MA regimen, the small dose CAG has a certain curative efficacy and survival rate, and the incidence of side effect reduced. Therefore, the small dose CAG is superior to MA for the senile patients with acute myeloid leukemia.